Drugs / [111In]-FPI-2058
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05605522 | Feb 2023 → Jul 2024 | Ewing sarcoma, colorectal cancer, gastric cancer, head and neck squamous cell carcinoma +2 | 3B Pharmaceuticals GmbH | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [111In]-FPI-2058 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05605522 ↗ |
| Modality | Diagnostic / imaging agent | “\[111In\]-FPI-2058 is an imaging agent” NCT05605522 ↗ |
| Route | Intravenous | “Participants will receive \[111In\]-FPI-2058 by IV Injection for imaging once during screening period.” NCT05605522 ↗ |